SCHEMBL3710490

SCHEMBL3710490

COCCN1CC(=O)N(CCc2cccs2)C(CC(=O)NCCc2ccc(OC)c(OC)c2)C1=O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
POLB P06746 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 2/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 1/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707428 0.96 ALDH1A1 (0.52) ALDH1A1POLBSMN1; SMN2KMT2AMEN1
SCHEMBL3702254 0.92 POLB (0.53) ALDH1A1POLBKMT2AMEN1GAA
SCHEMBL3700786 0.91 ALDH1A1 (0.49) ALDH1A1POLBSMN1; SMN2KMT2AMEN1
SCHEMBL3708113 0.90 HPGD (0.53) ALDH1A1POLBSMN1; SMN2KMT2AMEN1
SCHEMBL3705173 0.89 KMT2A (0.43) ALDH1A1POLBSMN1; SMN2KMT2AMEN1
SCHEMBL3697576 0.89 ACHE (0.54) ALDH1A1POLBSMN1; SMN2KMT2AMEN1
SCHEMBL3697169 0.88 MAPT (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1GAA
SCHEMBL3705701 0.88 APAF1 (0.45) ALDH1A1POLBSMN1; SMN2KMT2AMEN1
SCHEMBL3698041 0.88 KMT2A (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1GAA
SCHEMBL9885457 0.86 KMT2A (0.41) ALDH1A1POLBSMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
EP-2460798-A2 APAF-1 INHIBITOR COMPOUNDS Laboratorios SALVAT, S.A. (ES) 2012-06-06 EP disclosed
EP-2460798-A2 APAF-1 INHIBITOR COMPOUNDS Laboratorios SALVAT, S.A. (ES) 2012-06-06 EP disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS APAF1, API5, AIFM1 ALDH1A1 701/4885POLB 1562/4885SMN1; SMN2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.